Therapeutic Approach

Archive: January, 2017

Ritter Pharmaceuticals to Ring Today’s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month

LOS ANGELES (January 30, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, will be ringing the closing bell for the Nasdaq stock market in New York today, Monday, January 30, 2017 at 4:00 p.m. EST […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome

LOS ANGELES (January 23, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is collaborating with the newly-established Food for Health Center at the University of Nebraska (“NU”) to study the […]

Leave Your Comments »

Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors

LOS ANGELES (January 17, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced it has appointed William Merino, Ph.D., to its Board of Directors. Dr. Merino will occupy a newly-created seat, advising on regulatory, […]

Leave Your Comments »

Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences

LOS ANGELES (January 3, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that clinical microbiome data from its Phase 2a clinical trial of RP-G28 in patients with lactose intolerance were published in the […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD